Published in Am J Pathol on September 01, 2006
Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest (2008) 5.85
Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest (2007) 5.19
Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A (2007) 2.81
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) (2009) 2.35
B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol (2010) 1.77
Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol (2010) 1.61
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol (2008) 1.58
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest (2011) 1.50
Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation. J Leukoc Biol (2013) 1.48
Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 1.39
IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol (2011) 1.29
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol (2006) 1.24
Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res (2009) 1.24
CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.24
CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol (2008) 1.23
B cells and immunological tolerance. J Invest Dermatol (2009) 1.15
Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum (2010) 1.13
B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther (2010) 1.09
B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther (2013) 1.07
B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology (2010) 0.99
Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Rev Clin Immunol (2011) 0.88
Transient depletion of B cells in young mice results in activation of regulatory T cells that inhibit development of autoimmune disease in adults. Int Immunol (2012) 0.87
Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother (2010) 0.86
B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism. Clin Exp Immunol (2011) 0.86
Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int (2010) 0.85
Efficacy of rapamycin in scleroderma: a case study. Lymphat Res Biol (2008) 0.84
The role of B cells in systemic sclerosis. Biologics (2008) 0.84
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther (2012) 0.83
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Curr Rheumatol Rev (2010) 0.82
B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol (2011) 0.82
B cells and transplantation: an educational resource. Biol Blood Marrow Transplant (2009) 0.80
Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther (2016) 0.79
B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther (2013) 0.79
Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol (2009) 0.78
Efficient B cell depletion via diphtheria toxin in CD19-Cre/iDTR mice. PLoS One (2013) 0.78
Abnormal B lymphocyte activation and function in systemic sclerosis. Ann Dermatol (2015) 0.78
Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice. J Immunol (2014) 0.78
B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals. Int Immunol (2010) 0.78
Challenges and opportunities in treating inflammation associated with pulmonary hypertension. Expert Rev Cardiovasc Ther (2016) 0.76
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. J Transl Med (2014) 0.76
Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int (2012) 0.76
B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther (2016) 0.75
Cytokines in the immunopathology of systemic sclerosis. Semin Immunopathol (2015) 0.75
B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis. Front Immunol (2017) 0.75
[Anti-B-cell strategies in vasculitides and collagenoses]. Z Rheumatol (2009) 0.75
Pathogenesis of systemic sclerosis-current concept and emerging treatments. Immunol Res (2017) 0.75
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol (2004) 6.75
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.11
A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn (2001) 3.10
Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum (1988) 2.93
Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A (2003) 2.87
Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity (1995) 2.69
CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity (1996) 2.28
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol (2005) 2.16
Mouse CD20 expression and function. Int Immunol (2004) 2.02
Cellular infiltrates in scleroderma skin. Arthritis Rheum (1977) 1.96
CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol (1996) 1.90
Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol (1976) 1.85
Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol (2005) 1.84
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest (1992) 1.79
CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest (2002) 1.61
A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res (1996) 1.57
CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry (1993) 1.46
Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol (1991) 1.45
Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol (2000) 1.44
Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum (2004) 1.37
Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol (1999) 1.36
New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1 mutation in the tight skin mouse. J Cell Biol (2000) 1.30
Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest (1993) 1.21
Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci U S A (2002) 1.19
Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) (2004) 1.15
Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol (2001) 1.13
A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol (1999) 1.10
CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol (1994) 1.09
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol (2002) 1.08
Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol (1999) 1.07
Autoantibodies in scleroderma and tightskin mice. Curr Opin Immunol (1994) 1.04
Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol (1998) 1.02
B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol (2004) 1.02
The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun (2005) 1.01
Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun (1993) 1.01
A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol (1994) 1.00
CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol (1996) 1.00
B-cell deficiency does not abrogate development of cutaneous hyperplasia in mice inheriting the defective fibrillin-1 gene. J Autoimmun (1997) 0.96
Fibulin-2 and fibulin-5 alterations in tsk mice associated with disorganized hypodermal elastic fibers and skin tethering. J Invest Dermatol (2004) 0.96
Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents. Lab Invest (2005) 0.96
Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum (2004) 0.95
Increased collagen biosynthesis and increased expression of type I and type III procollagen genes in tight skin (TSK) mouse fibroblasts. J Biol Chem (1986) 0.95
Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice. Autoimmunity (1998) 0.94
Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype". J Immunol (2005) 0.93
Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun Rev (2002) 0.93
Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum (2003) 0.90
Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene. Mol Med (2000) 0.88
Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum (2001) 0.87
Correlation between the concentration of serum anti-topoisomerase I autoantibodies and histological and biochemical alterations in the skin of tight skin mice. Cell Immunol (1996) 0.87
The tight-skin mouse: physical and biochemical properties of the skin. J Rheumatol (1983) 0.87
The role of mast cells in the development of skin fibrosis in tight-skin mutant mice. Comp Biochem Physiol A Physiol (1995) 0.86
Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol (1989) 0.86
Effect of IL-12 encoding plasmid administration on tight-skin mouse. Biochem Biophys Res Commun (2001) 0.84
Immunological characterization of (tight skin/NZB)F1 hybrid mice with connective tissue and autoimmune features resembling human systemic sclerosis. J Autoimmun (1993) 0.83
CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response. J Invest Dermatol (2005) 0.83
The mouse tight skin (Tsk) phenotype is not dependent on the presence of mature T and B lymphocytes. Mamm Genome (1998) 0.82
Adoptive transfer of tsk skin fibrosis to +/+ recipients by tsk bone marrow and spleen cells. Proc Soc Exp Biol Med (1989) 0.80
Effect of targeted mutation in collagen V alpha 2 gene on development of cutaneous hyperplasia in tight skin mice. Mol Med (1998) 0.77
A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity (2008) 6.73
Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest (2008) 5.85
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med (2011) 5.16
Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science (2009) 4.45
B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity (2005) 4.31
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood (2010) 4.28
B lymphocytes: how they develop and function. Blood (2008) 4.07
Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev (2008) 3.67
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature (2012) 3.48
B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci (2010) 3.07
B-lymphocyte contributions to human autoimmune disease. Immunol Rev (2008) 2.89
The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol (2009) 2.87
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A (2007) 2.81
B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 2.79
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum (2006) 2.72
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol (2008) 2.45
Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol (2010) 2.44
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res (2011) 2.23
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol (2005) 2.16
CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol (2004) 2.16
Poor glycemic control is a major factor in the overestimation of glomerular filtration rate in diabetic patients. Diabetes Care (2013) 2.15
Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol (2011) 2.15
CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest (2009) 2.15
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol (2007) 2.05
Mouse CD20 expression and function. Int Immunol (2004) 2.02
Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol (2015) 1.99
Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol (2010) 1.98
B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol (2008) 1.96
The joint impact on being overweight of self reported behaviours of eating quickly and eating until full: cross sectional survey. BMJ (2008) 1.83
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke (2004) 1.79
B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol (2010) 1.77
Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med (2004) 1.70
IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther (2013) 1.66
CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest (2002) 1.61
Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol (2010) 1.61
Effects of habitual alcohol intake on ambulatory blood pressure, heart rate, and its variability among Japanese men. Hypertension (2008) 1.60
Metabolic Syndrome and the Risk of Ischemic Heart Disease and Stroke among Middle-Aged Japanese. Hypertens Res (2008) 1.59
Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum (2012) 1.56
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood (2008) 1.55
Guidelines for management of atopic dermatitis. J Dermatol (2009) 1.54
Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med (2011) 1.53
CD83 expression influences CD4+ T cell development in the thymus. Cell (2002) 1.52